Investigating the link between unexplained polyneuropathy and wild-type TTR cardiac amyloidosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore the prevalence of wild-type TTR cardiac amyloidosis in patients suffering from chronic axonal length-dependent polyneuropathy (CAP) and/or small-fiber neuropathy (SFN) of unknown cause. Participants will undergo a series of assessments, including symptom evaluation, electrocardiograms, and echocardiography, to determine if these neuropathies are early manifestations of cardiac amyloidosis. The goal is to facilitate faster diagnosis and improve clinical outcomes for patients with this condition. Data from previous medical evaluations will also be analyzed to support the findings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with chronic axonal length-dependent polyneuropathy (CAP) and/or small-fiber neuropathy (SFN) without well-defined etiology.
* Age: \>= 60 years
* Male and female gender
* Written informed consent

Exclusion Criteria:

* Known cause of polyneuropathy
* Other types of peripheral neuropathy than chronic axonal length-dependent polyneuropathy (CAP) and/or small-fiber neuropathy (SFN).
* Patients younger than 60 years

Where it's running

• UZ Brussel
  Jette, Belgium Capital City, Belgium Recruiting

Study contacts

• Principal investigator: Veronique Bissay, MD, Phd — UZ Brussel - VUB
• Study coordinator: Véronique Bissay, MD,Phd
• Email: veronique.bissay@uzbrussel.be
• Phone: +32 2 477 68 01

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acoramidis for ATTR-CM: Cardiac Imaging Study

  This study tests whether acoramidis can improve heart structure and function in people with transthyretin amyloid cardiomyopathy.

  Recruiting Phase 4 Eidos Therapeutics, a BridgeBio company · St Louis, Missouri · NCT07695701

• Heart-Healthy Rehab for Cardiac Amyloidosis

  This study tests whether a 5-week supervised cardiac rehabilitation program can help people with cardiac amyloidosis improve exercise capacity and quality of life.

  Recruiting University Hospital, Montpellier · Montpellier · NCT07494942

• SCTC21C plus bortezomib, cyclophosphamide and dexamethasone for newly diagnosed systemic light-chain (AL) amyloidosis

  This trial tests whether adding SCTC21C to standard bortezomib‑cyclophosphamide‑dexamethasone (VCd) helps people with newly diagnosed AL (light‑chain) amyloidosis achieve better hematologic responses and outcomes.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing, Beijing Municipality · NCT07388602

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• 18F‑FT8 PET imaging for light‑chain (AL) cardiac amyloidosis

  This project tests whether a new PET tracer, 18F‑FT8, can safely and clearly image light‑chain (AL) cardiac amyloidosis in adults with suspected or known disease and in healthy volunteers.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT07232459

• Belantamab Mafodotin with a chemotherapy combo for newly diagnosed AL amyloidosis

  This study tests whether adding belantamab mafodotin to a regimen of cyclophosphamide, bortezomib, and dexamethasone can help adults with newly diagnosed AL amyloidosis.

  Recruiting at 16 sites Phase 2 GlaxoSmithKline · Los Angeles, California and 15 other locations · NCT07224672

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.